Clinical trial
Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed…
NCT00132054 · Japan Multinational Trial Organization, Other · Completed
Key facts
| NCT number | NCT00132054 |
|---|---|
| Title | Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer |
| Official title | Phase I Study of Weekly Irinotecan Combined With Amrubicin in Previously Treated Small-Cell Lung Cancer |
| Lead sponsor | Japan Multinational Trial Organization, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | amrubicin hydrochloride, irinotecan hydrochloride |
| Enrollment | 30 |
| Start date | May 1, 2004 |
| Primary completion | Dec 1, 2006 |
| Completion | Nov 1, 2008 |
| First posted | Aug 19, 2005 |
| Last update posted | May 30, 2013 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: